News & Media

MEDIAN Technologies and CANON will introduce the LMS solutions at ITEM, April 13-15, 2012, Yokohama, Japan.

10 April 2012, Sophia Antipolis, France

This joint presentation results from the strategic agreement signed between the two entities in July, 2011.

MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials and clinical routine, announced today it will demonstrate its Lesion Management Solutions –LMS- clinical application portfolio together with Canon at ITEM, April 13-15, 2012 in Yokohama, Japan.

This joint presentation results from the strategic partnership agreement signed between Canon Inc and MEDIAN Technologies in July, 2011, with three major objectives:

  • To develop new  Computer-Aided Diagnosis/Detection (CAD) products and services,
  • To make these innovative solutions available to hospitals and biopharmaceutical companies through a cloud-based Software as a Service (SaaS) offering,
  • To establish major clinical partnerships in Japan and Asia in particular to validate new imaging solutions developed through the partnership.

“We have been working very closely with CANON Inc. since the signature of our long-term partnership”, said Gerard Milhiet, MEDIAN Executive Vice President and co-founder.”We are thrilled to support CANON in exploring new opportunities in the region by leveraging existing LMS applications as well as upcoming co-developed LMS solutions in the context of oncology clinical routine and clinical trials, healthcare IT solutions, and lung cancer screening”.

The International Technical Exhibition of Medical Imaging (ITEM) is an academic exhibition organized as a part of JRC 2012 by the Japan Industries Association of Radiological Systems (JIRA). This annual exhibition covers a wide range of medical diagnostic imaging devices with related appliances.

About LMS (Lesion Management Solutions)

MEDIAN Lesion Management Solutions detect, evaluate and follow-up lesions identified in computed tomography (CT) scans. The LMS perform a number of measurements automatically (such as lesion dimensions, volume and density); these parameters are used in both routine clinical practice and during clinical trials to evaluate patient responses to cancer therapies.

LMS are adaptable and compatible with all CT scanners. They can be integrated into heterogeneous IT environments and easily installed on sites with very diverse equipment and software configurations. MEDIAN LMS are provided as “Software as A Service”; they are web-based, fully distributed and available anywhere in the world.

About Median Technologies.

Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.

Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”

Contacts

MEDIAN Technologies

Fredrik Brag
CEO
+33 4 92 90 65 82
fredrik.brag@mediantechnologies.com

Actifin (Investors)

Ghislaine Gasparetto
+33 1 56 88 11 11
ggasparetto@actifin.fr

Alizé RP (Press)

Caroline Carmagnol
Wendy Rigal

+33 1 44 54 36 66
median@alizerp.com

Cookies help us deliver our services. By using our services, you agree to our use of cookies.